Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Hormone therapy affects plasma measures of factor VII-activating protease in younger postmenopausal women

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Mathiasen, Jørn Sidelmann ; Skouby, S.O. ; Vitzthum, F. ; Schwarz, H. ; Jespersen, J. / Hormone therapy affects plasma measures of factor VII-activating protease in younger postmenopausal women. In: Climacteric. 2010 ; Vol. 13, No. 4. pp. 340-346.

Bibtex

@article{1dffcea0b2c949ea8a6312437dd27e7e,
title = "Hormone therapy affects plasma measures of factor VII-activating protease in younger postmenopausal women",
abstract = "Objectives Current reviews indicate that hormone therapy (HT) has a protective role in coronary heart disease (CHD) in younger postmenopausal women, whereas HT contributes to CHD in older women Factor VII-activating protease (FSAP) is a serine protease that accumulates in unstable atherosclerotic plaques. FSAP is presumably involved in plaque stability and rupture. Reduced plasma concentration of FSAP may be associated with the development and expression of atherosclerosis and may thus contribute to precipitation of CHD. Here we address the potential influence of various HT regimens on plasma measures of FSAP in postmenopausal women treated for I year with different HT formulations or no HT. Methods Six groups of postmenopausal women (n = 139) were allocated to five different HT modalities or no HT Samples were collected at baseline and after 12 months of treatment. Prototype assays were used for the determination of FSAP antigen and FSAP activity. Results The FSAP measures were comparable at baseline. No significant changes were observed in the control group after 12 months. HT in general induced a significant increase in FSAP antigen (7.7 mu g/ml at baseline and 8.0 mu g/ml after 12 months, p = 0.05), FSAP activity (1 54 PEU/ml at baseline and 1.68 PEU/ml after 12 months, p <0.001) and FSAP ratio (202 mPEU/mu g at baseline and 210 mPEU/mu g after 12 months, p = 0.01). Conclusions HT increases the plasma measures of FSAP. This increase may contribute to the protective effect on CHD induced by HT in younger postmenopausal women",
author = "Mathiasen, {J{\o}rn Sidelmann} and S.O. Skouby and F. Vitzthum and H. Schwarz and J. Jespersen",
year = "2010",
doi = "10.3109/13697131003597027",
language = "English",
volume = "13",
pages = "340--346",
journal = "Climacteric",
issn = "1369-7137",
publisher = "Informa Healthcare",
number = "4",

}

RIS

TY - JOUR

T1 - Hormone therapy affects plasma measures of factor VII-activating protease in younger postmenopausal women

AU - Mathiasen, Jørn Sidelmann

AU - Skouby, S.O.

AU - Vitzthum, F.

AU - Schwarz, H.

AU - Jespersen, J.

PY - 2010

Y1 - 2010

N2 - Objectives Current reviews indicate that hormone therapy (HT) has a protective role in coronary heart disease (CHD) in younger postmenopausal women, whereas HT contributes to CHD in older women Factor VII-activating protease (FSAP) is a serine protease that accumulates in unstable atherosclerotic plaques. FSAP is presumably involved in plaque stability and rupture. Reduced plasma concentration of FSAP may be associated with the development and expression of atherosclerosis and may thus contribute to precipitation of CHD. Here we address the potential influence of various HT regimens on plasma measures of FSAP in postmenopausal women treated for I year with different HT formulations or no HT. Methods Six groups of postmenopausal women (n = 139) were allocated to five different HT modalities or no HT Samples were collected at baseline and after 12 months of treatment. Prototype assays were used for the determination of FSAP antigen and FSAP activity. Results The FSAP measures were comparable at baseline. No significant changes were observed in the control group after 12 months. HT in general induced a significant increase in FSAP antigen (7.7 mu g/ml at baseline and 8.0 mu g/ml after 12 months, p = 0.05), FSAP activity (1 54 PEU/ml at baseline and 1.68 PEU/ml after 12 months, p <0.001) and FSAP ratio (202 mPEU/mu g at baseline and 210 mPEU/mu g after 12 months, p = 0.01). Conclusions HT increases the plasma measures of FSAP. This increase may contribute to the protective effect on CHD induced by HT in younger postmenopausal women

AB - Objectives Current reviews indicate that hormone therapy (HT) has a protective role in coronary heart disease (CHD) in younger postmenopausal women, whereas HT contributes to CHD in older women Factor VII-activating protease (FSAP) is a serine protease that accumulates in unstable atherosclerotic plaques. FSAP is presumably involved in plaque stability and rupture. Reduced plasma concentration of FSAP may be associated with the development and expression of atherosclerosis and may thus contribute to precipitation of CHD. Here we address the potential influence of various HT regimens on plasma measures of FSAP in postmenopausal women treated for I year with different HT formulations or no HT. Methods Six groups of postmenopausal women (n = 139) were allocated to five different HT modalities or no HT Samples were collected at baseline and after 12 months of treatment. Prototype assays were used for the determination of FSAP antigen and FSAP activity. Results The FSAP measures were comparable at baseline. No significant changes were observed in the control group after 12 months. HT in general induced a significant increase in FSAP antigen (7.7 mu g/ml at baseline and 8.0 mu g/ml after 12 months, p = 0.05), FSAP activity (1 54 PEU/ml at baseline and 1.68 PEU/ml after 12 months, p <0.001) and FSAP ratio (202 mPEU/mu g at baseline and 210 mPEU/mu g after 12 months, p = 0.01). Conclusions HT increases the plasma measures of FSAP. This increase may contribute to the protective effect on CHD induced by HT in younger postmenopausal women

U2 - 10.3109/13697131003597027

DO - 10.3109/13697131003597027

M3 - Journal article

VL - 13

SP - 340

EP - 346

JO - Climacteric

JF - Climacteric

SN - 1369-7137

IS - 4

ER -

ID: 32300449